Literature DB >> 15184423

Comparison of quantitative and semiquantitative enzyme-linked immunosorbent assays for immunoglobulin G against Chlamydophila pneumoniae to a microimmunofluorescence test for use with patients with respiratory tract infections.

Corinna Hermann1, Katja Gueinzius, Albrecht Oehme, Sonja Von Aulock, Eberhard Straube, Thomas Hartung.   

Abstract

We previously reported a high degree of variation in the sensitivities of serodiagnostic kits for the detection of Chlamydophila pneumoniae in sera from healthy donors. Since a low predictive value of a test can impair its diagnostic value, we have extended our studies to samples from patients with pneumonia. We focused on the most promising enzyme-linked immunosorbent assays (ELISAs) (SeroCP and SeroCP Quant; Savyon) identified in our previous study and included a new ELISA (sELISA; Medac). The agreement between all ELISAs for immunoglobulin G (IgG) and a reference microimmunofluorescence (MIF) test for IgG (SeroFIA; Savyon) was > or = 90% for a collective of 80 patients. The positive predictive values were all > or = 93%. The negative predictive values ranged from 68 to 83%. False-negative results were obtained only for samples that had low titers in the MIF test. The correlation of the IgG antibody titers determined by the MIF and SeroCP Quant tests was high (r(sp) = 0.9). Since the semiquantitative SeroCP and quantitative SeroCP Quant ELISAs achieved the highest sensitivities, they were evaluated further by using a second batch of sera from 50 patients with predominantly medium and low antibody titers in the MIF test and a control collection of sera from 80 children with negative MIF results. Again, the tests showed a high concordance with the MIF results (96%), and the antibody titers in the SeroCP Quant and MIF tests correlated well (r(sp) = 0.8). The specificities determined with the negative sera were > or = 99% for the SeroCP Quant test and 86% for the SeroCP test. These results show that ELISAs that are fast and objective deliver seroprevalence results, sensitivities, and specificities that are very similar to those of the MIF test.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15184423      PMCID: PMC427843          DOI: 10.1128/JCM.42.6.2476-2479.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  34 in total

Review 1.  Chlamydia pneumoniae and the lung.

Authors:  M R Hammerschlag
Journal:  Eur Respir J       Date:  2000-11       Impact factor: 16.671

2.  Multicenter comparison trial of DNA extraction methods and PCR assays for detection of Chlamydia pneumoniae in endarterectomy specimens.

Authors:  P Apfalter; F Blasi; J Boman; C A Gaydos; M Kundi; M Maass; A Makristathis; A Meijer; R Nadrchal; K Persson; M L Rotter; C Y Tong; G Stanek; A M Hirschl
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

3.  Replicate PCR testing and probit analysis for detection and quantitation of Chlamydia pneumoniae in clinical specimens.

Authors:  M Smieja; J B Mahony; C H Goldsmith; S Chong; A Petrich; M Chernesky
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

Review 4.  Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada).

Authors:  S F Dowell; R W Peeling; J Boman; G M Carlone; B S Fields; J Guarner; M R Hammerschlag; L A Jackson; C C Kuo; M Maass; T O Messmer; D F Talkington; M L Tondella; S R Zaki
Journal:  Clin Infect Dis       Date:  2001-07-20       Impact factor: 9.079

Review 5.  Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease.

Authors:  Murat V Kalayoglu; Peter Libby; Gerald I Byrne
Journal:  JAMA       Date:  2002-12-04       Impact factor: 56.272

6.  Evaluation of a commercial test for antibodies to the chlamydial lipopolysaccharide (Medac) for serodiagnosis of acute infections by Chlamydia pneumoniae (TWAR) and Chlamydia psittaci.

Authors:  K Persson; S Haidl
Journal:  APMIS       Date:  2000-02       Impact factor: 3.205

Review 7.  Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response.

Authors:  J Mestecky; J R McGhee
Journal:  Adv Immunol       Date:  1987       Impact factor: 3.543

Review 8.  Chlamydia pneumoniae infection of the central nervous system.

Authors:  C Yucesan; S Sriram
Journal:  Curr Opin Neurol       Date:  2001-06       Impact factor: 5.710

9.  IgA antibody-producing cells in peripheral blood after antigen ingestion: evidence for a common mucosal immune system in humans.

Authors:  C Czerkinsky; S J Prince; S M Michalek; S Jackson; M W Russell; Z Moldoveanu; J R McGhee; J Mestecky
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

10.  Association of circulating Chlamydia pneumoniae DNA with cardiovascular disease: a systematic review.

Authors:  Marek Smieja; James Mahony; Astrid Petrich; Jens Boman; Max Chernesky
Journal:  BMC Infect Dis       Date:  2002-10-01       Impact factor: 3.090

View more
  3 in total

1.  Acute hemorrhagic pericarditis in a child with pneumonia due to Chlamydophila pneumoniae.

Authors:  T Tenenbaum; A Heusch; B Henrich; C R MacKenzie; K G Schmidt; H Schroten
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

2.  Comparative Seroepidemiologic Analysis of Chlamydophila Pneumoniae Infection using Microimmunofluorescence, Enzyme Immunoassay and Neutralization Test: Implications for Serodiagnosis.

Authors:  M C Phoon; Gabriel W J Yee; Woon-Puay Koh; Vincent T K Chow
Journal:  Indian J Microbiol       Date:  2011-02-16       Impact factor: 2.461

3.  Serological Analysis and Drug Resistance of Chlamydia pneumoniae and Mycoplasma pneumoniae in 4500 Healthy Subjects in Shenzhen, China.

Authors:  Dong Du; Shuping Liao; Yan Wu; Yang Jiao; Di Wu; Weiqing Wu; Dapeng Yu
Journal:  Biomed Res Int       Date:  2017-09-19       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.